Inovio Pharmaceuticals
INO
133 hedge funds and large institutions have $118M invested in Inovio Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 19 closing their positions.
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
6% more funds holding
Funds holding: 125 → 133 (+8)
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
0.04% less ownership
Funds ownership: 2.69% → 2.64% (-0.04%)
20% less call options, than puts
Call options by funds: $405K | Put options by funds: $504K
36% less capital invested
Capital invested by funds: $184M → $118M (-$66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.88M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.65M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.29M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$738K |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$735K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.84M |
| 2 |
Morgan Stanley
New York
|
-$3M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.64M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$739K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$731K |
INO Hedge Fund Activity: Q4 2017 in Review
133 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2017, worth a combined $118M — down 36% from $184M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new INO positions and 19 closed out — a net gain of 8 holders — while 36 added to existing stakes and 33 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.88M. The largest seller was Millennium Management, cutting an estimated $5.84M.
- 133 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2017, up from 125 in Q3 2017.
- Funds reported $118M of Inovio Pharmaceuticals stock for Q4 2017, down 36% quarter-over-quarter.
- 27 funds opened new Inovio Pharmaceuticals positions in Q4 2017 and 19 closed out, a net change of +8 holders.
- The largest Inovio Pharmaceuticals buyer in Q4 2017 was Renaissance Technologies, an estimated $1.88M added.
- The largest Inovio Pharmaceuticals seller in Q4 2017 was Millennium Management, an estimated $5.84M sold.
Based on aggregated 13F filings for Q4 2017.